Pharma Equity Group A/S Cl A
The answer first
Does Pharma Equity Group A/S Cl beat the market?
No, Pharma Equity Group A/S Cl has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 2% of Nordic stocks
- Quality13
- Value7
- Trend24
No. 187 of 195 in healthcare
Max for seven days
Follow Pharma Equity Group A/S Cl with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Pharma Equity Group A/S Cl
Your first answer is free, no account needed.
Do you own Pharma Equity Group A/S Cl, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Pharma Equity Group A/S Cl and a few more. Free, no card.
Super Stock+44.6%In short
- Pharma Equity Group A/S Cl has fallen 38.6% over the past year, including dividends.
- Overall, Pharma Equity Group A/S Cl ranks better than 2% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 93.9%. The price is 99.9% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 2% of Nordic stocks.
No. 187 of 195 in healthcare
Low Weaker accounts than most: low profitability, high debt or uneven results.
No. 182 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.44
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−72.0%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 151 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity3.3
- P/SPrice divided by sales19.9
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 115 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−13.2%
- 6 months−8.4%
- 9 months−23.1%
- 12 months−38.6%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Pharma Equity Group A/S Cl
4 funds we follow own Pharma Equity Group A/S Cl. The share is how much of the fund the stock makes up.
- Denmark4
From the funds' latest known holdings.
About Pharma Equity Group A/S Cl
Pharma Equity Group A/S Cl A is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 5 employees.
Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which the current therapy is lacking or in need of improvement. Its products under development, includes RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX-051 for the treatment of colorectal cancer and colon adenoma that are in Phase II clinical trials. The company was incorporated in 2002 and is headquartered in Horsholm, Denmark.


See the full analysis of Pharma Equity Group A/S Cl.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card